Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

Nature Structural and Molecular Biology

Volumn 11, Issue 5, 2004, Pages 412-419

  Harel, Michal ^a   Aharoni, Amir ^a   Gaidukov, Leonid ^a   Brumshtein, Boris ^a   Khersonsky, Olga ^a   Meged, Ran ^a   Dvir, Hay ^a   Ravelli, Raimond B G ^b   McCarthy, Andrew ^b   Toker, Lilly ^a   Silman, Israel ^a   Sussman, Joel L ^a   Tawfik, Dan S ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CATALYSIS; CRYSTAL STRUCTURE; DETOXIFICATION; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; ENZYME SUBSTRATE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; ARYLDIALKYLPHOSPHATASE; CATALYSIS; EVOLUTION, MOLECULAR; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

INVERTEBRATA; MAMMALIA; VERTEBRATA;

EID: 2342569704     PISSN: 15459993     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsmb767     Document Type: Article

References (38)

1. Draganov, D.I. & La Du, B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369, 78-88 (2004).
2. Lusis, A.J. Atherosclerosis. Nature 407, 233-241 (2000).
3. Shih, D.M. et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287 (1998).
4. Mackness, M.I., Arrol, S. & Durrington, P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density-lipoprotein. FEBS Lett. 286, 152-154 (1991).
5. Reddy, S.T. et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21, 542-547 (2001).
6. Rodrigo, L., Mackness, B., Durrington, P.N., Hernandez, A. & Mackness, M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354, 1-7 (2001).
7. Ahmed, Z. et al. Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J. Biol. Chem. 276, 24473-24481 (2001).
8. Jakubowski, H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275, 3957-3962 (2000).
9. Lund-Katz, S., Liu, L.J., Thuahnai, S.T. & Phillips, M.C. High density lipoprotein structure. Front. Biosci. 8, D1044-D1054 (2003).
10. Fuhrman, B., Volkova, N. & Aviram, M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 161, 307-316 (2002).
11. Rozenberg, O., Shih, D.M. & Aviram, M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A(2)-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 23, 461-467 (2003).
12. Sorenson, R.C. et al. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19, 2214-2225 (1999).
13. Aharoni, A. et al. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. USA 101, 482-487 (2004).
14. Fokine, A. et al. Direct phasing at low resolution of a protein copurified with human paraoxonase (PON1). Acta Crystallogr. D. 59, 2083-2087 (2003).
15. Josse, D. et al. Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J. Biol. Chem. 277, 33386-33397 (2002).
16. Kuo, C.L. & La Du, B.N. Comparison of purified human and rabbit serum paraoxonases. Drug Metab. Dispos. 23, 935-944 (1995).
17. Jawad, Z. & Paoli, M. Novel sequences propel familiar folds. Structure 10, 447-454 (2002).
18. Kuo, C.L. & La Du, B.N. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab. Dispos. 26, 653-60 (1998).
19. Scharff, E.I., Koepke, J., Fritzsch, G., Lucke, C. & Ruterjans, H. Crystal structure of diisopropylfluorophosphatase from Loligo vulgaris. Structure 9, 493-502 (2001).
20. Josse, D. et al. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 38, 2816-2825 (1999).
21. Jonas, A. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta 1529, 245-256 (2000).
22. Josse, D. et al. The active site of human paraoxonase (PON1). J. Appl. Toxicol. 21, S7-S11 (2001).
23. Josse, D., Xie, W.H., Masson, P., Schopfer, L.M. & Lockridge, O. Tryptophan residue(s) as major components of the human serum paraoxonase active site. Chem. Biol. Interact. 120, 79-84 (1999).
24. Sekar, K. et al. Phospholipase A2 engineering. Structural and functional roles of the highly conserved active site residue aspartate-99. Biochemistry 36, 3104-3114 (1997).
25. Aviram, M. et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18, 1617-1624 (1998).
26. Kobayashi, M., Shinohara, M., Sakoh, C., Kataoka, M. & Shimizu, S. Lactone-ring-cleaving enzyme: genetic analysis, novel RNA editing, and evolutionary implications. Proc. Natl. Acad. Sci. USA 95, 12787-12792 (1998).
27. Chelur, D.S. et al. The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel. Nature 420, 669-73 (2002).
28. Navab, M. et al. High density associated enzymes: their role in vascular biology. Curr. Opin. Lipidol. 9, 449-456 (1998).
29. Borhani, D.W., Rogers, D.P., Engler, J.A. & Brouillette, C.G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc. Natl. Acad. Sci. USA 94, 12291-12296 (1997).
30. Segrest, J.P., Harvey, S.C. & Zannis, V. Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications. Trends Cardiovasc. Med. 10, 246-252 (2000).
31. Killian, J.A. & von Heijne, G. How proteins adapt to a membrane-water interface. Trends Biochem. Sci. 25, 429-434 (2000).
32. Waldo, G.S. Genetic screens and directed evolution for protein solubility. Curr. Opin. Chem. Biol. 7, 33-38 (2003).
33. Bencharit, S., Morton, C.L., Xue, Y., Potter, P.M. & Redinbo, M.R. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat. Struct. Biol. 10, 349-356 (2003).
34. Millard, C.B., Lockridge, O. & Broomfield, C.A. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry 37, 237-247 (1998).
35. Greenblatt, H.M., Dvir, H., Silman, I. & Sussman, J.L. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J. Mol. Neurosci. 20, 369-383 (2003).
36. Leviev, I., Deakin, S. & James, R.W. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J. Lipid Res. 42, 528-535 (2001).
37. Oda, M.N., Bielicki, J.K., Berger, T. & Forte, T.M. Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry 40, 1710-1718 (2001).
38. Lee, B. & Richards, F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55, 379-389 (1971).